论文部分内容阅读
据近期出版的《获得性免疫缺陷综合征》杂志报道,一项研究结果显示 atazanavir 替代包含其他种类蛋白酶抑制剂的治疗可改善 HIV 感染者因抗逆转录病毒治疗引发的代谢紊乱综合征。来自于德国 Hannover 医学院的 Ulrike Mobius 博士对路透健康记者说,对高血脂症和具有心血管事件高风险因子的患者来说,Atazanavir 治疗是一个很好的选择。Moebius 博士及其同事对33例患有严重高血脂症的 HIV 患者分别给予 atazanavir 制剂治疗,并对治疗后的血脂变化及其药效进行了评估研究,其中26例患者在接受 atazanavir 治疗前一直使用某种蛋白酶抑制剂进行治疗。
According to a recent issue of Acquired Immunodeficiency Syndrome, one study showed that atazanavir replacement therapy with other classes of protease inhibitors can improve the metabolic syndrome caused by antiretroviral therapy in HIV-infected individuals. Dr. Ulrike Mobius, from Hannover Medical School in Germany, told Reuters Health reporters that Atazanavir is a good choice for patients with hyperlipidemia and high-risk cardiovascular events. Dr. Moebius and his colleagues treated atazanavir in 33 HIV-positive patients with severe hyperlipidemia and evaluated the changes in blood lipids and their pharmacodynamics after treatment, of which 26 were used until atazanavir treatment Some kind of protease inhibitor for treatment.